Company profile for MetasTx

NEW Drugs in Dev: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK). An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%. Thi...
MetasTx is developing a pipeline of novel cancer agents targeted at specific solid tumors based on advances in the delivery of IPA-3, a highly selective inhibitor of Group-1 P21 activated kinases (PAK). An estimated 608,570 Americans died from cancer in 2021. The five-year survival rate of metastatic cancers, those that travel from the primary site to a distant site (also known as Stage 4 or 5), is approximately 30%. This area of research is ripe for advances. Unfortunately, current drug discovery in metastatic cancer has not resulted in therapies with significant increases in patient survival, specificity in drug delivery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
162 Smoke Rise Road Baskin Ridge, New Jersey 07920-3710
Telephone
Telephone
+1 908-432-2150
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/07/3162913/0/en/NJ-Founded-MetasTx-Fast-Tracks-Precision-Approach-to-Stop-Prostate-Cancer-Spread-NCI-Backed-Diagnostic-in-Proof-of-Concept-Next-Gen-KIT-Inhibitor-Advancing-Toward-First-in-Human.html

GLOBENEWSWIRE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/06/25/3104963/0/en/MetasTx-Secures-NCI-Grant-to-Enable-the-Advancement-of-Dual-Track-Strategy-Against-Metastatic-Prostate-Cancer.html

GLOBENEWSWIRE
25 Jun 2025

https://www.globenewswire.com/news-release/2024/09/13/2945866/0/en/MetasTx-Welcomes-Esteemed-Cancer-Scientist-Dr-Jonathan-Chernoff-to-the-Board-of-Managers.html

GLOBENEWSWIRE
13 Sep 2024

https://www.globenewswire.com/news-release/2024/09/12/2945043/0/en/Harvey-Homan-to-Highlight-MetasTx-s-Game-Changing-Approach-to-Cancer-Treatment-at-PA-Life-Science-Futures.html

GLOBENEWSWIRE
12 Sep 2024

https://www.globenewswire.com/news-release/2022/08/29/2505830/0/en/Renown-Cancer-Expert-Joins-MetasTx-s-Scientific-Advisory-Board.html#:~:text=On%20adding%20Dr.%20Chernoff%20to,in%20the%20cancer%20research%20community.

GLOBENEWSWIRE
29 Aug 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty